Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Aug 12, 2009


UK-based DxS has appointed Dave Clennell as its new director of quality.

"With demand for the company's range of mutation test kits continuing to increase, and an imminent FDA pre-market submission for DxS' TheraScreen: K-RAS Mutation Kit clinical diagnostic in the US, this is a key leadership appointment for DxS at a time of rapid growth," the company said in a statement.

Prior to joining DxS, Clennell was the international director of quality at Lombard Medical Technologies. He has also held various leadership roles overseeing the quality of products at Johnson & Johnson, Genzyme, and SmithKline Beecham Pharmaceuticals.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.